Clinical Trial

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.
Protocol Amendment History 1 change
minor Completion moved earlier: 2027-06-30 -> 2026-08-18 2026-07-07
Trial Details
NCT Number NCT02494986
Lead Sponsor Janssen Sciences Ireland UC
Conditions Human Immunodeficiency Virus Type 1
Enrollment 48 participants
Start Date 2015-07-06
Primary Completion 2026-08-18 (estimated)
Study Completion 2026-08-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-06